Basic Information
| Drug ID | DDPD00900 |
|
| Drug Name | Didanosine | |
| Molecular Weight | 236.2273 | |
| Molecular Formula | C10H12N4O3 | |
| CAS Number | 69655-05-6 | |
| SMILES | OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O | |
| External Links | ||
| DRUGBANK | DB00900 | |
| T3DB | T3D4786 | |
| PubChem Compound | 50599 | |
| PDR | 912 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | -1.24 | - | -1.24 | - | SANGSTER (1993) |
| Melting Point | 134.5 | ℃ | 160-163 | ℃ | PhysProp |
| Water Solubility | 15800.0 | mg/L | 15.8 | mg/ml | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Bioavailability | 35.0 | % | 30-40 | % | DRUGBANK | Bioavailability | 38.0 | % | 38±15 | % | PO, oral; | The Pharmacological Basis of Therapeutics |
| C Max | 1500.0 | ng/ml | 1.5±0.7 | mcg/ml | Tablet, PO, oral; fasting; extended release formulation; AIDS,HIV; | The Pharmacological Basis of Therapeutics | C Max | 930.0 | ng/ml | 0.93±0.43 | mcg/ml | PO, oral; fasting; extended release formulation; AIDS,HIV; | The Pharmacological Basis of Therapeutics |
| T Max | 1.0 | h | 0.5-1.5 | h | DRUGBANK | T Max | 0.67 | h | 0.67(0.33-1.33) | h | Tablet, PO, oral; fasting; extended release formulation; AIDS,HIV; | The Pharmacological Basis of Therapeutics | T Max | 2.0 | h | 2.0(1.0-5.0) | h | PO, oral; fasting; extended release formulation; AIDS,HIV; | The Pharmacological Basis of Therapeutics |
| Clearance | 0.96 | L/h/kg | 16±7 | ml/min/kg | Children → ; | The Pharmacological Basis of Therapeutics | Clearance | 0.66 | L/h/kg | 11 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 1.0 | L/kg | 1.0±0.2 | L/kg | The Pharmacological Basis of Therapeutics | Volume of Distribution | 0.77 | L/kg | 0.77 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 0.50 | h | 30 | min | DRUGBANK | Half-life | 12.0 | h | >12 | h | DRUGBANK | Half-life | 1.4 | h | 1.4±0.3 | h | The Pharmacological Basis of Therapeutics | Half-life | 1.4 | h | 1.4 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Eliminate Route | 36.0 | % | 36±9 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics | |
| Protein Binding | 5.0 | % | <5 | % | DRUGBANK | Protein Binding | 5.0 | % | <5 | % | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for neonates | 200.0 | mg/m2/day | 200 | mg/m2/day | Liquid | Videx | didanosine | PDR |
| Max dose for neonates | 100.0 | mg/m2/day | 100 | mg/m2/day | Videx | didanosine | PDR | |
| Max dose for infants | 240.0 | mg/m2/day | 240 | mg/m2/day | Liquid | Videx | didanosine | PDR |
| Max dose for infants | 300.0 | mg/m2/day | 300 | mg/m2/day | Videx | didanosine | PDR | |
| Max dose for infants | 200.0 | mg/m2/day | 200 | mg/m2/day | Liquid | Videx | didanosine | PDR |
| Max dose for infants | 200.0 | mg/m2/day | 200 | mg/m2/day | Liquid | Videx | didanosine | PDR |
| Max dose for infants | 100.0 | mg/m2/day | 100 | mg/m2/day | Videx | didanosine | PDR | |
| Max dose for children | 400.0 | mg/day | 400 | mg/day | Capsule, PO, Oral | Videx | didanosine | PDR |
| Max dose for children | 240.0 | mg/m2/day | 240 | mg/m2/day | Liquid | Videx | didanosine | PDR |
| Max dose for children | 300.0 | mg/m2/day | 300 | mg/m2/day | Videx | didanosine | PDR | |
| Max dose for children | 400.0 | mg/day | 400 | mg/day | Videx | didanosine | PDR | |
| Max dose for children | 250.0 | mg/day | 250 | mg/day | Capsule, PO, Oral | Videx | didanosine | PDR |
| Max dose for children | 240.0 | mg/m2/day | 240 | mg/m2/day | Liquid | Videx | didanosine | PDR |
| Max dose for children | 300.0 | mg/m2/day | 300 | mg/m2/day | Videx | didanosine | PDR | |
| Max dose for children | 250.0 | mg/day | 250 | mg/day | Videx | didanosine | PDR | |
| Max dose for children | 200.0 | mg/day | 200 | mg/day | Capsule, PO, Oral | Videx | didanosine | PDR |
| Max dose for children | 240.0 | mg/m2/day | 240 | mg/m2/day | Liquid | Videx | didanosine | PDR |
| Max dose for children | 300.0 | mg/m2/day | 300 | mg/m2/day | Videx | didanosine | PDR | |
| Max dose for children | 250.0 | mg/day | 250 | mg/day | Videx | didanosine | PDR | |
| Max dose for children | 240.0 | mg/m2/day | 240 | mg/m2/day | Liquid | Videx | didanosine | PDR |
| Max dose for children | 300.0 | mg/m2/day | 300 | mg/m2/day | Videx | didanosine | PDR | |
| Max dose for adolescents | 400.0 | mg/day | 400 | mg/day | Capsule, PO, Oral | Videx | didanosine | PDR |
| Max dose for adolescents | 240.0 | mg/m2/day | 240 | mg/m2/day | Liquid | Videx | didanosine | PDR |
| Max dose for adolescents | 300.0 | mg/m2/day | 300 | mg/m2/day | Videx | didanosine | PDR | |
| Max dose for adolescents | 400.0 | mg/day | 400 | mg/day | Videx | didanosine | PDR | |
| Max dose for adolescents | 250.0 | mg/day | 250 | mg/day | Capsule, PO, Oral | Videx | didanosine | PDR |
| Max dose for adolescents | 240.0 | mg/m2/day | 240 | mg/m2/day | Liquid | Videx | didanosine | PDR |
| Max dose for adolescents | 300.0 | mg/m2/day | 300 | mg/m2/day | Videx | didanosine | PDR | |
| Max dose for adolescents | 250.0 | mg/day | 250 | mg/day | Videx | didanosine | PDR | |
| Max dose for adolescents | 200.0 | mg/day | 200 | mg/day | Capsule, PO, Oral | Videx | didanosine | PDR |
| Max dose for adolescents | 240.0 | mg/m2/day | 240 | mg/m2/day | Liquid | Videx | didanosine | PDR |
| Max dose for adolescents | 300.0 | mg/m2/day | 300 | mg/m2/day | Videx | didanosine | PDR | |
| Max dose for adolescents | 250.0 | mg/day | 250 | mg/day | Videx | didanosine | PDR | |
| Max dose for adults | 400.0 | mg/day | 400 | mg/day | PO, oral | Videx | didanosine | PDR |
| Max dose for adults | 250.0 | mg/day | 250 | mg/day | PO, oral | Videx | didanosine | PDR |
| Max dose for geriatric | 400.0 | mg/day | 400 | mg/day | PO, oral | Videx | didanosine | PDR |
| Max dose for geriatric | 250.0 | mg/day | 250 | mg/day | PO, oral | Videx | didanosine | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1